{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-25-000036","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.979000+00:00","generated_at":"2026-05-22T08:52:13.232856+00:00","sec_items":["2.02","5.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data","bullets":["Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.","Cash $100.6M as of Mar 31, down from $112.4M; company expects runway into 2027.","CFO Gemma Brown terminated Apr 30 in restructuring; CEO William Enright named principal financial officer, Brown stays as principal accounting officer until successor.","HBV003 trial: 33% (15/45) of low baseline HBsAg participants achieved ≥1 log decline; 71% met NUC discontinuation criteria; no SAEs.","IM-PROVE II: 25% (2/8) of participants with baseline HBsAg <1000 IU/mL reached functional cure; all seroconverted."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-25-000036","json":"https://secwatch.observer/filing/0001828185-25-000036.json","markdown":"https://secwatch.observer/filing/0001828185-25-000036.md","text":"https://secwatch.observer/filing/0001828185-25-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/brns-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:52:13.232856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16d84424d9","claim":"Gemma Brown was appointed as principal accounting officer at Barinthus Biotherapeutics plc..","evidence_excerpt":"and Ms. Brown as principal accounting officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}]},{"claim_id":"91f33b7c84","claim":"William Enright was appointed as principal financial officer at Barinthus Biotherapeutics plc..","evidence_excerpt":"appointed William Enright, the Company’s Chief Executive Officer, as principal financial officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer"}]},{"claim_id":"f3fb7e73b5","claim":"Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..","evidence_excerpt":"Effective as of April 30, 2025, the Company terminated the employment of Gemma Brown as Chief Financial Officer in connection with its restructuring plan that was announced in 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}